Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics

Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is strikingly effective in the initial stage of chronic myeloid leukemia with more than 90% of the patients showing complete remission. However, as in the case of most targeted anti-cancer therapies, the emergence...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovera, Silvia, Morando, Maria, Pucheta-Martinez, Encarna, Martinez-Torrecuadrada, Jorge L., Saladino, Giorgio, Gervasio, Francesco L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659586/
https://www.ncbi.nlm.nih.gov/pubmed/26606374
http://dx.doi.org/10.1371/journal.pcbi.1004578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659586/
https://www.ncbi.nlm.nih.gov/pubmed/26606374
http://dx.doi.org/10.1371/journal.pcbi.1004578

Ejemplares similares